Antibiotic Market Overview by Shares and Future Outlook to 2019-2024

of antibiotic drugs and significant R&D activities in the market are expected to fuel market growth in the upcoming
years.
Infection diseases such as Diarrhea is considered as one of the Major cause of high mortality rate among children,
particularly in the developing and underdeveloped economies all around the globe. Increasing use of antibiotic drugs to
prevent this morbidity is anticipated to augment market demand over the forecast period. Increasing number of cases
related to other infectious diseases such as HIV, pneumonia, malaria, and tuberculosis is further propelling market
growth since last couple of decades.
Moreover, surfacing of unfamiliar infections, such as Zika virus and Ebola, has led to the soaring demand of antibiotics
in the market. Recent collaborations among various private bodies and research institute with governmental agencies
and colleges to develop innovative techniques and products to fight against unfamiliar infections, such as Zika virus and
Ebola is predicted to fuel market growth over the forecast period.
Rising funding from regional governments for innovative R&D approaches is leading to the generation of new pipeline
products. However, complexity associated with development of advanced antibiotics and high initial cost are some of
the major restraining factors for market growth to a certain extent. Additionally, lack of awareness of these products in
underdeveloped economies and the high cost of development of the drugs is anticipated to limit market growth.
Get a Sample Copy of This Report @ https://www.millioninsights.com/industry-reports/antibioticsmarket/request-sample
The monoclonal antibodies is considered as one of the fastest growing segment in the antibiotics market with substantial
revenue generation in the last couple of years. Other market segment along with monoclonal antibodies such as
tetracyclines, imidazoles and lincosamides hold massive market share across the globe.
Numerous benefits of monoclonal antibodies over its counter parts is considered as major driving factor for the growth
of monoclonal antibodies market segment. Growing prevalence of pneumonia, blood stream infections, and urinary tract
infections (UTI) are predicted to boost the demand of carbapenems class of antibiotics.
The antibiotics market is divided by region as North America, Europe, Asia-Pacific, Latin America and Africa. Latin
America has shown major growth in recent years owing to the rise in the implementation of latest technologies in
pharmaceuticals & medicine sector, strong economic growth in the region, and existence of well-established healthcare
infrastructure.
Asia-Pacific region is predicted to hold major market share in the antibiotics market with massive growth in forecast
period. Countries such as India, China and Japan are leading the Asia-Pacific’s market with increasing occurrence of
infectious diseases, ever-growing population in developing economies, favorable governmental regulation and reforms,
increasing use of generic medicines, and significant investment by leading industry players considering potential growth
opportunities in the region.
The key players in the antibiotics market are Pfizer Incorporations, Janssen Pharmaceuticals, Inc., Abbott Laboratories,
GlaxoSmithKline plc, Sanofi S.A., Novartis AG, Bayer AG, Bristol Myers Squibb Company, Eli Lilly and Company
Co., and Astellas Pharma Incorporations.